Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 10/20 | 0.57 |
| ▸ | TGFBR2 | P37173 | 6/20 | 0.51 |
| ▸ | GSK3B | P49841 | 6/20 | 0.39 |
| ▸ | DYRK1A | Q13627 | 6/20 | 0.39 |
| ▸ | WNT1 | P04628 | 4/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.37 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.37 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.37 |
| ▸ | CDC7 | O00311 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17840548 | 0.88 | TGFBR1 (0.60) | TGFBR1TGFBR2GSK3BDYRK1AWNT1 | |
| SCHEMBL17840836 | 0.86 | TGFBR1 (0.58) | TGFBR1TGFBR2GSK3BDYRK1AKDM4E | |
| SCHEMBL17840643 | 0.86 | TGFBR1 (0.58) | TGFBR1TGFBR2GSK3BDYRK1AKDM4E | |
| SCHEMBL17840617 | 0.82 | TGFBR1 (0.57) | TGFBR1TGFBR2GSK3BDYRK1AWNT1 | |
| SCHEMBL17840955 | 0.82 | TGFBR1 (0.57) | TGFBR1TGFBR2GSK3BDYRK1AWNT1 | |
| SCHEMBL17840820 | 0.82 | TGFBR1 (0.57) | TGFBR1TGFBR2GSK3BDYRK1AWNT1 | |
| SCHEMBL17840570 | 0.81 | TGFBR1 (0.64) | TGFBR1TGFBR2GSK3BSMN1; SMN2TLR9 | |
| SCHEMBL17840954 | 0.81 | TGFBR1 (0.56) | TGFBR1TGFBR2KDM4E | |
| SCHEMBL17840666 | 0.81 | TGFBR1 (0.70) | TGFBR1TGFBR2 | |
| SCHEMBL17840736 | 0.81 | TGFBR1 (0.82) | TGFBR1TGFBR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9708316-B2 | TGFβR antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-07-18 | — | — | US | disclosed |
| US-9708316-B2 | TGFβR antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-07-18 | — | — | US | disclosed |
| US-9708316-B2 | TGFβR antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-07-18 | — | — | US | disclosed |
| WO-2016106266-A1 | TGFβ RECEPTOR ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-06-30 | — | — | WO | disclosed |
| US-20160176871-A1 | TGF BETA R ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY | 2016-06-23 | — | — | US | disclosed |
| US-20160176871-A1 | TGF BETA R ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY | 2016-06-23 | — | — | US | disclosed |
| US-20160176871-A1 | TGF BETA R ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY | 2016-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160176871-A1 | TGF BETA R ANTAGONISTS | TGFBR2, TGFBR1, TGFB1 | TGFBR1 2/4885TGFBR2 1/4885GSK3B 33/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.